University Hospital Galway
- Address
- lock Available on a paid plan
Oncology and Genetic Phenomena
At University Hospital Galway, oncology research focuses on melanoma, breast cancer, and chronic lymphocytic leukemia, with studies also addressing ER+/HER2- early breast cancer. These trials are designed to compare new treatment approaches with current standards and to help reduce the risk of cancer recurrence or disease progression.
- Testing new immunotherapy combinations for melanoma after surgery
- Evaluating endocrine-based options to prevent breast cancer recurrence
- Comparing treatment strategies for previously untreated chronic lymphocytic leukemia
Overall, this area of research aims to improve long-term outcomes by identifying more effective and better-targeted cancer treatments.
Immune System Diseases and Skin and Connective Tissue Diseases
Clinical trials in immune-related and dermatology conditions at this site include atopic dermatitis, hidradenitis suppurativa, and other inflammatory skin disorders. The research is centered on finding therapies that can better control symptoms and help patients who have not responded well to existing treatments.
- Assessing new treatment options for moderate to severe atopic dermatitis
- Studying therapies for hidradenitis suppurativa in adolescents and adults
- Exploring improved control of chronic inflammatory skin disease
These studies reflect a strong interest in advancing care for persistent immune-mediated and skin conditions.
Virus Diseases and Respiratory Tract Diseases
Research in this area addresses COVID-19, severe community-acquired pneumonia, and mpox virus disease. The trials are focused on evaluating treatments for hospitalized patients, understanding clinical outcomes, and improving care during serious infectious illnesses.
- Testing therapies for hospitalized patients with moderate and severe COVID-19
- Evaluating treatment approaches for severe pneumonia
- Observing outcomes in patients with mpox virus disease
This infectious disease portfolio highlights efforts to improve recovery and survival in acute viral and respiratory illness.
Digestive System Diseases and Nutritional and Metabolic Diseases
Studies in digestive and metabolic medicine include ulcerative colitis, obesity, and classic congenital adrenal hyperplasia. The research is aimed at improving long-term disease control, reducing treatment burden, and identifying safer or more effective therapies.
- Assessing long-term treatment options for ulcerative colitis
- Investigating new approaches for obesity and related cardiometabolic risk
- Evaluating therapies that may reduce glucocorticoid use in congenital adrenal hyperplasia
These trials show a broad interest in chronic conditions that affect digestion, hormones, and metabolism.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 17 therapeutic areas and 15 of 183 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 180 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 36 by active trials.
lock +35 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Cancer Trials Ireland6trials
lock +21 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 45 other sites in Ireland
Therapeutic Area Benchmark — Ireland
Select a therapeutic area to compare against other sites in Ireland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Ireland
Market Share
Country: Ireland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Hospital Galway
lock Showing 1 of 88 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 183 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 8 | Unknown | 2016-02-19 | 2025-09-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.